{"id":26667,"date":"2023-04-27T12:49:47","date_gmt":"2023-04-27T16:49:47","guid":{"rendered":"https:\/\/capital10x.com\/old\/?p=26667"},"modified":"2023-04-27T12:49:47","modified_gmt":"2023-04-27T16:49:47","slug":"mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds","status":"publish","type":"post","link":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/","title":{"rendered":"Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds"},"content":{"rendered":"<p><strong>Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF)<\/strong> a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it has filed two international patent applications under the Patent Coorperation Treaty (\u201cPCT\u201d) for the protection of certain of Mindset\u2019s non-hallucinogenic novel non-tryptamine compounds known as \u201cFamily 6.\u201d<\/p>\n<p>The filings are based on pre-clinical studies and provide Mindset with preliminary freedom to operate for all claimed drug candidates from Family 6.<\/p>\n<div class=\"su-quote su-quote-style-default su-quote-has-cite\"><div class=\"su-quote-inner su-u-clearfix su-u-trim\">By applying Mindset\u2019s innovative drug discovery and development platform on novel psychedelic-inspired non-hallucinogenic drug candidates, we have begun to see results. We believe that this class of drugs may have the potential to treat a substantially wider patient population including fragile population groups such as children or geriatric patients.<\/p>\n<p>&nbsp;<\/p>\n<p>Additionally, by reducing or removing the psychedelic effect, in-clinic supervision should not be necessary, in turn reducing cost and improving convenience of these treatment options. The pre-clinical study results underpinning the candidates identified in these patent applications are highly promising.<\/p>\n<p>Work performed on these novel non-tryptamine candidates, which included in-vitro screening, and ADME (absorption, distribution, metabolism, and excretion), along with in vivo studies, indicates 5-HT2A serotonin receptor activation without the cardinal in vivo signs of a hallucinogenic effect.<span class=\"su-quote-cite\">James Lanthier, CEO of Mindset Pharma<\/span><\/div><\/div>\n<p><strong>Mindset\u2019s CEO and CSO discussing the Announcement:<\/strong><\/p>\n<div class=\"youtube-embed\" data-video_id=\"x8bRpfpDnb0\"><iframe loading=\"lazy\" title=\"Mindset Expands Drug Discovery Platform\" width=\"696\" height=\"392\" src=\"https:\/\/www.youtube.com\/embed\/x8bRpfpDnb0?feature=oembed&#038;enablejsapi=1\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" allowfullscreen><\/iframe><\/div>\n<p><strong>About Mindset Pharma Inc.<\/strong><\/p>\n<p>Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable best-in-class innovative next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybins in addition to its own proprietary compounds.<\/p>\n<p>The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, covering multiple drug development programs.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it has filed two international patent applications under the Patent Coorperation Treaty (\u201cPCT\u201d) for the protection of certain of Mindset\u2019s non-hallucinogenic novel non-tryptamine compounds known as \u201cFamily 6.\u201d<\/p>\n","protected":false},"author":25,"featured_media":24065,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[56,1112],"tags":[2202,2109,2287,2203,1824,2288],"class_list":{"0":"post-26667","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-featured","8":"category-tech","9":"tag-cse-mset","10":"tag-investing-in-psychedelics","11":"tag-mindset-pharma-inc","12":"tag-otcqb-msstf","13":"tag-psychedelics","14":"tag-psychedelics-stocks"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds | Capital 10X<\/title>\n<meta name=\"description\" content=\"Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it has filed two international patent applications under the Patent Coorperation Treaty (\u201cPCT\u201d) for the protection of certain of Mindset\u2019s non-hallucinogenic novel non-tryptamine compounds known as \u201cFamily 6.\u201d\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds | Capital 10X\" \/>\n<meta property=\"og:description\" content=\"Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it has filed two international patent applications under the Patent Coorperation Treaty (\u201cPCT\u201d) for the protection of certain of Mindset\u2019s non-hallucinogenic novel non-tryptamine compounds known as \u201cFamily 6.\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/\" \/>\n<meta property=\"og:site_name\" content=\"Capital 10X\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Capital10x\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-27T16:49:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-11.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1069\" \/>\n\t<meta property=\"og:image:height\" content=\"713\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Duane Hope\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@capital10x\" \/>\n<meta name=\"twitter:site\" content=\"@capital10x\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Duane Hope\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/\"},\"author\":{\"name\":\"Duane Hope\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851\"},\"headline\":\"Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds\",\"datePublished\":\"2023-04-27T16:49:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/\"},\"wordCount\":359,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/capital10x.com\/old\/#organization\"},\"image\":{\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-11.jpg\",\"keywords\":[\"CSE: MSET\",\"investing in psychedelics\",\"Mindset Pharma Inc.\",\"OTCQB: MSSTF\",\"Psychedelics\",\"psychedelics stocks\"],\"articleSection\":[\"Featured\",\"Health &amp; Tech\"],\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\/\/capital10x.com\/old\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/\",\"url\":\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/\",\"name\":\"Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds | Capital 10X\",\"isPartOf\":{\"@id\":\"https:\/\/capital10x.com\/old\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-11.jpg\",\"datePublished\":\"2023-04-27T16:49:47+00:00\",\"description\":\"Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it has filed two international patent applications under the Patent Coorperation Treaty (\u201cPCT\u201d) for the protection of certain of Mindset\u2019s non-hallucinogenic novel non-tryptamine compounds known as \u201cFamily 6.\u201d\",\"breadcrumb\":{\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#primaryimage\",\"url\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-11.jpg\",\"contentUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-11.jpg\",\"width\":1069,\"height\":713},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/capital10x.com\/old\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Featured\",\"item\":\"https:\/\/capital10x.com\/old\/featured\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/capital10x.com\/old\/#website\",\"url\":\"https:\/\/capital10x.com\/old\/\",\"name\":\"Capital 10X\",\"description\":\"Identifying 10X Investment Opportunities\",\"publisher\":{\"@id\":\"https:\/\/capital10x.com\/old\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/capital10x.com\/old\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/capital10x.com\/old\/#organization\",\"name\":\"Capital 10X\",\"url\":\"https:\/\/capital10x.com\/old\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png\",\"contentUrl\":\"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png\",\"width\":128,\"height\":90,\"caption\":\"Capital 10X\"},\"image\":{\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Capital10x\/\",\"https:\/\/x.com\/capital10x\",\"https:\/\/www.instagram.com\/capital10x\",\"https:\/\/www.linkedin.com\/company\/capital10x\/\",\"https:\/\/www.pinterest.com\/capital10x\",\"https:\/\/www.youtube.com\/Capital10X\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851\",\"name\":\"Duane Hope\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capital10x.com\/old\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g\",\"caption\":\"Duane Hope\"},\"description\":\"Duane Hope is a Partner at Capital 10X, he brings over 15 years of communications and research experience to the firm. His research and writing has appeared in publications for North American, European and Asian audiences.\",\"sameAs\":[\"http:\/\/capital10x.com\"],\"url\":\"https:\/\/capital10x.com\/old\/author\/duanehope\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds | Capital 10X","description":"Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it has filed two international patent applications under the Patent Coorperation Treaty (\u201cPCT\u201d) for the protection of certain of Mindset\u2019s non-hallucinogenic novel non-tryptamine compounds known as \u201cFamily 6.\u201d","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/","og_locale":"en_US","og_type":"article","og_title":"Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds | Capital 10X","og_description":"Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it has filed two international patent applications under the Patent Coorperation Treaty (\u201cPCT\u201d) for the protection of certain of Mindset\u2019s non-hallucinogenic novel non-tryptamine compounds known as \u201cFamily 6.\u201d","og_url":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/","og_site_name":"Capital 10X","article_publisher":"https:\/\/www.facebook.com\/Capital10x\/","article_published_time":"2023-04-27T16:49:47+00:00","og_image":[{"width":1069,"height":713,"url":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-11.jpg","type":"image\/jpeg"}],"author":"Duane Hope","twitter_card":"summary_large_image","twitter_creator":"@capital10x","twitter_site":"@capital10x","twitter_misc":{"Written by":"Duane Hope","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#article","isPartOf":{"@id":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/"},"author":{"name":"Duane Hope","@id":"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851"},"headline":"Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds","datePublished":"2023-04-27T16:49:47+00:00","mainEntityOfPage":{"@id":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/"},"wordCount":359,"commentCount":0,"publisher":{"@id":"https:\/\/capital10x.com\/old\/#organization"},"image":{"@id":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#primaryimage"},"thumbnailUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-11.jpg","keywords":["CSE: MSET","investing in psychedelics","Mindset Pharma Inc.","OTCQB: MSSTF","Psychedelics","psychedelics stocks"],"articleSection":["Featured","Health &amp; Tech"],"inLanguage":"en-CA","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/capital10x.com\/old\/#organization"}},{"@type":"WebPage","@id":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/","url":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/","name":"Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds | Capital 10X","isPartOf":{"@id":"https:\/\/capital10x.com\/old\/#website"},"primaryImageOfPage":{"@id":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#primaryimage"},"image":{"@id":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#primaryimage"},"thumbnailUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-11.jpg","datePublished":"2023-04-27T16:49:47+00:00","description":"Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it has filed two international patent applications under the Patent Coorperation Treaty (\u201cPCT\u201d) for the protection of certain of Mindset\u2019s non-hallucinogenic novel non-tryptamine compounds known as \u201cFamily 6.\u201d","breadcrumb":{"@id":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/"]}]},{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#primaryimage","url":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-11.jpg","contentUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2022\/01\/mindset-11.jpg","width":1069,"height":713},{"@type":"BreadcrumbList","@id":"https:\/\/capital10x.com\/old\/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/capital10x.com\/old\/"},{"@type":"ListItem","position":2,"name":"Featured","item":"https:\/\/capital10x.com\/old\/featured\/"},{"@type":"ListItem","position":3,"name":"Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds"}]},{"@type":"WebSite","@id":"https:\/\/capital10x.com\/old\/#website","url":"https:\/\/capital10x.com\/old\/","name":"Capital 10X","description":"Identifying 10X Investment Opportunities","publisher":{"@id":"https:\/\/capital10x.com\/old\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/capital10x.com\/old\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-CA"},{"@type":"Organization","@id":"https:\/\/capital10x.com\/old\/#organization","name":"Capital 10X","url":"https:\/\/capital10x.com\/old\/","logo":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/","url":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png","contentUrl":"https:\/\/capital10x.com\/old\/wp-content\/uploads\/2019\/02\/capital-10X-logo-stacked.png","width":128,"height":90,"caption":"Capital 10X"},"image":{"@id":"https:\/\/capital10x.com\/old\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Capital10x\/","https:\/\/x.com\/capital10x","https:\/\/www.instagram.com\/capital10x","https:\/\/www.linkedin.com\/company\/capital10x\/","https:\/\/www.pinterest.com\/capital10x","https:\/\/www.youtube.com\/Capital10X\/"]},{"@type":"Person","@id":"https:\/\/capital10x.com\/old\/#\/schema\/person\/75fddffbd75d63e9226bc4c592e9a851","name":"Duane Hope","image":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capital10x.com\/old\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1e094aea10a79b65e157d5f0d9968719f11d1fafb952b910a18796349f2e38e9?s=96&d=mm&r=g","caption":"Duane Hope"},"description":"Duane Hope is a Partner at Capital 10X, he brings over 15 years of communications and research experience to the firm. His research and writing has appeared in publications for North American, European and Asian audiences.","sameAs":["http:\/\/capital10x.com"],"url":"https:\/\/capital10x.com\/old\/author\/duanehope\/"}]}},"_links":{"self":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts\/26667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/comments?post=26667"}],"version-history":[{"count":5,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts\/26667\/revisions"}],"predecessor-version":[{"id":26681,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/posts\/26667\/revisions\/26681"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/media\/24065"}],"wp:attachment":[{"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/media?parent=26667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/categories?post=26667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/capital10x.com\/old\/wp-json\/wp\/v2\/tags?post=26667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}